11 Nov 2022 , 04:03 PM
Net profit of Bafna Pharmaceuticals declined 32.35% to Rs 1.61 crore in the quarter ended September 2022 as against Rs 2.38 crore during the previous quarter ended September 2021. Sales declined 22.78% to Rs 21.96 crore in the quarter ended September 2022 as against Rs 28.44 crore during the previous quarter ended September 2021.
| Particulars | Quarter Ended | ||
| ? | Sep. 2022 | Sep. 2021 | % Var. |
| Sales | 21.96 | 28.44 | -23 |
| OPM % | 11.57 | 20.04 | – |
| PBDT | 2.73 | 5.77 | -53 |
| PBT | 1.61 | 4.35 | -63 |
| NP | 1.61 | 2.38 | -32 |
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
